| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2004.08.037 |
| P698 | PubMed publication ID | 15661389 |
| P50 | author | Bernard Roques | Q2898544 |
| Bernard A. Lafont | Q37649405 | ||
| Bruno Hurtrel | Q115605015 | ||
| Valérie Monceaux | Q115605017 | ||
| P2093 | author name string | Claude Desgranges | |
| Roger Le Grand | |||
| Sylviane Muller | |||
| Guillaume Belliard | |||
| Anne-Marie Aubertin | |||
| Emmanuel Moreau | |||
| P2860 | cites work | Quantifying the uncertainty in forecasts of anthropogenic climate change | Q28141336 |
| Tat as a transcriptional activator and a potential therapeutic target for HIV-1. | Q34033142 | ||
| From the outside in: extracellular activities of HIV Tat. | Q34033148 | ||
| The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals | Q34104267 | ||
| The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin | Q34123358 | ||
| Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication | Q34336210 | ||
| Tat-neutralizing antibodies in vaccinated macaques | Q34755910 | ||
| HIV-1 Tat-based vaccines: from basic science to clinical trials | Q34978901 | ||
| Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine | Q35993736 | ||
| Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. | Q36011366 | ||
| Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen | Q37010956 | ||
| Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein | Q39683362 | ||
| Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine | Q39699309 | ||
| Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR. | Q40887674 | ||
| HIV-1 Tat protein as a potential AIDS vaccine | Q41091310 | ||
| The human uniqueness of HIV: innate immunity and the viral Tat protein | Q43421877 | ||
| B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains | Q43499852 | ||
| Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine | Q44092065 | ||
| Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). | Q45012988 | ||
| Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides | Q45572850 | ||
| Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. | Q45722188 | ||
| SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. | Q45739668 | ||
| Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). | Q45742451 | ||
| Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients | Q47216468 | ||
| Evaluation in Rhesus Macaques of Tat and Rev-Targeted Immunization as a Preventive Vaccine against Mucosal Challenge with SHIV-BX08 | Q57081491 | ||
| Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine | Q59511395 | ||
| High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat, and vpu genes from HIV-1 Lai | Q71530285 | ||
| Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection | Q73138904 | ||
| Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals | Q73520478 | ||
| Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses | Q78417376 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1399-1407 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides | |
| P478 | volume | 23 |
| Q35785031 | A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe |
| Q27333734 | Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines |
| Q30381447 | HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. |
| Q39933791 | Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively |
| Q42930401 | Induction of anti-Tat neutralizing antibodies by the CyaA vector targeting dendritic cells: influence of the insertion site and of the delivery of multicopies of the dominant Tat B-cell epitope |
| Q34756847 | The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile |
Search more.